Swiss pharmaceutical group Roche has reported a four per cent increase in full-year net profit to SFr8.89 billion ($9.52 billion) in 2010.This content was published on February 2, 2011 - 08:44
Growth in sales of Roche's anti-cancer drugs was unable to compensate for a drop in sales of the group’s Tamiflu treatment and the surge in the Swiss franc. Full-year sales fell by three per cent to SFr47.47 billion, according to figures published on Wednesday.
Commenting on the Basel-based group’s performance, CEO Severin Schwan said the results were “solid despite an increasingly challenging market environment”.
Roche said it expects healthcare reforms in the United States and European austerity measures to dampen growth in 2011.
The group is hoping to save SFr1.8 billion in 2011 through a restructuring plan announced in November.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: email@example.com
In compliance with the JTI standards